TY - JOUR A1 - Busse, David A1 - Simon, Philipp A1 - Petroff, David A1 - El-Najjar, Nahed A1 - Schmitt, Lisa A1 - Bindellini, Davide A1 - Dietrich, Arne A1 - Zeitlinger, Markus A1 - Huisinga, Wilhelm A1 - Michelet, Robin A1 - Wrigge, Hermann A1 - Kloft, Charlotte T1 - High-dosage fosfomycin results in adequate plasma and target-site exposure in morbidly obese and nonobese nonhyperfiltration patients JF - Antimicrobial agents and chemotherapy N2 - The objectives of this study were the identification in (morbidly) obese and nonobese patients of (i) the most appropriate body size descriptor for fosfomycin dose adjustments and (ii) adequacy of the currently employed dosing regimens. Plasma and target site (interstitial fluid of subcutaneous adipose tissue) concentrations after fosfomycin administration (8 g) to 30 surgery patients (15 obese/15 nonobese) were obtained from a prospective clinical trial. After characterization of plasma and microdialysis-derived target site pharmacokinetics via population analysis, short-term infusions of fosfomycin 3 to 4 times daily were simulated. The adequacy of therapy was assessed by probability of pharmacokinetic/pharmacodynamic target attainment (PTA) analysis based on the unbound drug-related targets of an %fT(>= MIC) (the fraction of time that unbound fosfomycin concentrations exceed the MIC during 24 h) of 70 and an fAUC(0-24h)/MIC (the area under the concentration-time curve from 0 to 24 h for the unbound fraction of fosfomycin relative to the MIC) of 40.8 to 83.3. Lean body weight, fat mass, and creatinine clearance calculated via adjusted body weight (ABW) (CLCRCG_ABW) of all patients (body mass index [BMI] = 20.1 to 52.0 kg/m(2)) explained a considerable proportion of between-patient pharmacokinetic variability (up to 31.0% relative reduction). The steady-state unbound target site/plasma concentration ratio was 26.3% lower in (morbidly) obese than nonobese patients. For infections with fosfomycin-susceptible pathogens (MIC <= 16 mg/L), intermittent "high-dosage" intravenous (i.v.) fosfomycin (8 g, three times daily) was sufficient to treat patients with a CLCRCG_ABW of,130 mL/min, irrespective of the pharmacokinetic/pharmacodynamic indices considered. For infections by Pseudomonas aeruginosa with a MIC of 32 mg/L, when the index fAUC0-24h/MIC is applied, fosfomycin might represent a promising treatment option in obese and nonobese patients, especially in combination therapy to complement beta-lactams, in which carbapenem-resistant P. aeruginosa is critical. In conclusion, fosfomycin showed excellent target site penetration in obese and nonobese patients. Dosing should be guided by renal function rather than obesity status. KW - population pharmacokinetics KW - pharmacodynamics KW - fosfomycin KW - obesity KW - adipose tissue KW - interstitial space fluid KW - microdialysis KW - anti-infective KW - probability of target attainment Y1 - 2022 U6 - https://doi.org/10.1128/aac.02302-21 SN - 0066-4804 SN - 1098-6596 VL - 66 IS - 6 PB - American Society for Microbiology CY - Washington ER - TY - JOUR A1 - Lehn-Stefan, Angela A1 - Peter, Andreas A1 - Machann, Jürgen A1 - Schick, Fritz A1 - Randrianarisoa, Elko A1 - Heni, Martin A1 - Wagner, Robert A1 - Birkenfeld, Andreas L. A1 - Fritsche, Andreas A1 - Schulze, Matthias Bernd A1 - Stefan, Norbert A1 - Kantartzis, Konstantinos T1 - Impaired metabolic health and low cardiorespiratory fitness independently associate with subclinical atherosclerosis in obesity JF - The journal of clinical endocrinology & metabolism N2 - Context For a given body mass index (BMI), both impaired metabolic health (MH) and reduced cardiorespiratory fitness (CRF) associate with increased risk of cardiovascular disease (CVD). Objective It remains unknown whether both risk phenotypes relate to CVD independently of each other, and whether these relationships differ in normal weight, overweight, and obese subjects. Methods Data from 421 participants from the Tubingen Diabetes Family Study, who had measurements of anthropometrics, metabolic parameters, CRF (maximal aerobic capacity [VO2max]) and carotid intima-media thickness (cIMT), an early marker of atherosclerosis, were analyzed. Subjects were divided by BMI and MH status into 6 phenotypes. Results In univariate analyses, older age, increased BMI, and a metabolic risk profile correlated positively, while insulin sensitivity and VO2max negatively with cIMT. In multivariable analyses in obese subjects, older age, male sex, lower VO2max (std. ss -0.21, P = 0.002) and impaired MH (std. ss 0.13, P = 0.02) were independent determinants of increased cIMT. After adjustment for age and sex, subjects with metabolically healthy obesity (MHO) had higher cIMT than subjects with metabolically healthy normal weight (MHNW; 0.59 +/- 0.009 vs 0.52 +/- 0.01 mm; P < 0.05). When VO2max was additionally included in this model, the difference in cIMT between MHO and MHNW groups became statistically nonsignificant (0.58 +/- 0.009 vs 0.56 +/- 0.02 mm; P > 0.05). Conclusion These data suggest that impaired MH and low CRF independently determine increased cIMT in obese subjects and that low CRF may explain part of the increased CVD risk observed in MHO compared with MHNW. KW - Metabolically healthy obesity KW - cardiorespiratory fitness KW - subclinical KW - atherosclerosis KW - obesity KW - carotid intima-media thickness KW - cardiovascular KW - disease Y1 - 2022 U6 - https://doi.org/10.1210/clinem/dgac091 SN - 0021-972X SN - 1945-7197 VL - 107 IS - 6 SP - E2417 EP - E2424 PB - Endocrine Society CY - Washington ER - TY - JOUR A1 - Henning, Thorsten A1 - Kochlik, Bastian Max A1 - Kusch, Paula A1 - Strauss, Matthias A1 - Juric, Viktorija A1 - Pignitter, Marc A1 - Marusch, Frank A1 - Grune, Tilman A1 - Weber, Daniela T1 - Pre-Operative assessment of micronutrients, amino acids, phospholipids and oxidative stress in bariatric surgery candidates JF - Antioxidants : open access journal N2 - Obesity has been linked to lower concentrations of fat-soluble micronutrients and higher concentrations of oxidative stress markers as well as an altered metabolism of branched chain amino acids and phospholipids. In the context of morbid obesity, the aim of this study was to investigate whether and to which extent plasma status of micronutrients, amino acids, phospholipids and oxidative stress differs between morbidly obese (n = 23) and non-obese patients (n = 13). In addition to plasma, malondialdehyde, retinol, cholesterol and triglycerides were assessed in visceral and subcutaneous adipose tissue in both groups. Plasma gamma-tocopherol was significantly lower (p < 0.011) in the obese group while other fat-soluble micronutrients showed no statistically significant differences between both groups. Branched-chain amino acids (all p < 0.008) and lysine (p < 0.006) were significantly higher in morbidly obese patients compared to the control group. Malondialdehyde concentrations in both visceral (p < 0.016) and subcutaneous (p < 0.002) adipose tissue were significantly higher in the morbidly obese group while plasma markers of oxidative stress showed no significant differences between both groups. Significantly lower plasma concentrations of phosphatidylcholine, phosphatidylethanolamine, lyso-phosphatidylethanolamine (all p < 0.05) and their corresponding ether-linked analogs were observed, which were all reduced in obese participants compared to the control group. Pre-operative assessment of micronutrients in patients undergoing bariatric surgery is recommended for early identification of patients who might be at higher risk to develop a severe micronutrient deficiency post-surgery. Assessment of plasma BCAAs and phospholipids in obese patients might help to differentiate between metabolic healthy patients and those with metabolic disorders. KW - obesity KW - micronutrients KW - oxidative stress KW - amino acids KW - phospholipids KW - vitamins KW - plasma Y1 - 2022 U6 - https://doi.org/10.3390/antiox11040774 SN - 2076-3921 VL - 11 IS - 4 PB - MDPI CY - Basel ER - TY - JOUR A1 - Göldel, Julia M. A1 - Kamrath, Clemens A1 - Minden, Kirsten A1 - Wiegand, Susanna A1 - Lanzinger, Stefanie A1 - Sengler, Claudia A1 - Weihrauch-Blüher, Susann A1 - Holl, Reinhard W. A1 - Tittel, Sascha René A1 - Warschburger, Petra T1 - Access to Healthcare for Children and Adolescents with a Chronic Health Condition during the COVID-19 Pandemic: First Results from the KICK-COVID Study in Germany JF - Children N2 - This study examines the access to healthcare for children and adolescents with three common chronic diseases (type-1 diabetes (T1D), obesity, or juvenile idiopathic arthritis (JIA)) within the 4th (Delta), 5th (Omicron), and beginning of the 6th (Omicron) wave (June 2021 until July 2022) of the COVID-19 pandemic in Germany in a cross-sectional study using three national patient registries. A paper-and-pencil questionnaire was given to parents of pediatric patients (<21 years) during the routine check-ups. The questionnaire contains self-constructed items assessing the frequency of healthcare appointments and cancellations, remote healthcare, and satisfaction with healthcare. In total, 905 parents participated in the T1D-sample, 175 in the obesity-sample, and 786 in the JIA-sample. In general, satisfaction with healthcare (scale: 0–10; 10 reflecting the highest satisfaction) was quite high (median values: T1D 10, JIA 10, obesity 8.5). The proportion of children and adolescents with canceled appointments was relatively small (T1D 14.1%, JIA 11.1%, obesity 20%), with a median of 1 missed appointment, respectively. Only a few parents (T1D 8.6%; obesity 13.1%; JIA 5%) reported obstacles regarding health services during the pandemic. To conclude, it seems that access to healthcare was largely preserved for children and adolescents with chronic health conditions during the COVID-19 pandemic in Germany. KW - chronic health condition KW - children and adolescents KW - health care KW - COVID-19 pandemic KW - diabetes KW - rheumatic diseases KW - obesity Y1 - 2022 U6 - https://doi.org/10.3390/children10010010 SN - 2227-9067 VL - 10 SP - 1 EP - 11 PB - MDPI CY - Basel, Schweiz ET - 1 ER - TY - JOUR A1 - Püschel, Gerhard A1 - Klauder, Julia A1 - Henkel-Oberländer, Janin T1 - Macrophages, low-grade inflammation, insulin resistance and hyperinsulinemia BT - A mutual ambiguous relationship in the development of metabolic diseases JF - Journal of Clinical Medicine : open access journal N2 - Metabolic derangement with poor glycemic control accompanying overweight and obesity is associated with chronic low-grade inflammation and hyperinsulinemia. Macrophages, which present a very heterogeneous population of cells, play a key role in the maintenance of normal tissue homeostasis, but functional alterations in the resident macrophage pool as well as newly recruited monocyte-derived macrophages are important drivers in the development of low-grade inflammation. While metabolic dysfunction, insulin resistance and tissue damage may trigger or advance pro-inflammatory responses in macrophages, the inflammation itself contributes to the development of insulin resistance and the resulting hyperinsulinemia. Macrophages express insulin receptors whose downstream signaling networks share a number of knots with the signaling pathways of pattern recognition and cytokine receptors, which shape macrophage polarity. The shared knots allow insulin to enhance or attenuate both pro-inflammatory and anti-inflammatory macrophage responses. This supposedly physiological function may be impaired by hyperinsulinemia or insulin resistance in macrophages. This review discusses the mutual ambiguous relationship of low-grade inflammation, insulin resistance, hyperinsulinemia and the insulin-dependent modulation of macrophage activity with a focus on adipose tissue and liver. KW - NAFLD/MAFLD KW - type 2 diabetes KW - obesity KW - vicious cycle KW - TLR signaling KW - M1/M2 differentiation KW - Akt pathway Y1 - 2022 U6 - https://doi.org/10.3390/jcm11154358 SN - 2077-0383 VL - 11 IS - 15 SP - 1 EP - 30 PB - MDPI CY - Basel, Schweiz ER - TY - JOUR A1 - Hauffe, Robert A1 - Rath, Michaela A1 - Agyapong, Wilson A1 - Jonas, Wenke A1 - Vogel, Heike A1 - Schulz, Tim Julius A1 - Schwarz, Maria A1 - Kipp, Anna Patricia A1 - Blüher, Matthias A1 - Kleinridders, André T1 - Obesity Hinders the Protective Effect of Selenite Supplementation on Insulin Signaling JF - Antioxidants N2 - The intake of high-fat diets (HFDs) containing large amounts of saturated long-chain fatty acids leads to obesity, oxidative stress, inflammation, and insulin resistance. The trace element selenium, as a crucial part of antioxidative selenoproteins, can protect against the development of diet-induced insulin resistance in white adipose tissue (WAT) by increasing glutathione peroxidase 3 (GPx3) and insulin receptor (IR) expression. Whether selenite (Se) can attenuate insulin resistance in established lipotoxic and obese conditions is unclear. We confirm that GPX3 mRNA expression in adipose tissue correlates with BMI in humans. Cultivating 3T3-L1 pre-adipocytes in palmitate-containing medium followed by Se treatment attenuates insulin resistance with enhanced GPx3 and IR expression and adipocyte differentiation. However, feeding obese mice a selenium-enriched high-fat diet (SRHFD) only resulted in a modest increase in overall selenoprotein gene expression in WAT in mice with unaltered body weight development, glucose tolerance, and insulin resistance. While Se supplementation improved adipocyte morphology, it did not alter WAT insulin sensitivity. However, mice fed a SRHFD exhibited increased insulin content in the pancreas. Overall, while selenite protects against palmitate-induced insulin resistance in vitro, obesity impedes the effect of selenite on insulin action and adipose tissue metabolism in vivo. KW - selenite KW - insulin KW - adipose tissue KW - obesity KW - insulin resistance Y1 - 2022 U6 - https://doi.org/10.3390/antiox11050862 SN - 2076-3921 VL - 11 SP - 1 EP - 16 PB - MDPI CY - Basel, Schweiz ET - 5 ER - TY - THES A1 - Schell, Mareike T1 - Investigating the effect of Lactobacillus rhamnosus GG on emotional behavior in diet-induced obese C57BL/6N mice T1 - Untersuchung der Wirkung von Lactobacillus rhamnosus GG bei Störungen des emotionalen Verhaltens in einem Mausmodell Diät-induzierter Adipositas N2 - The prevalence of depression and anxiety is increased in obese patients compared to healthy humans, which is partially due to a shared pathogenesis, including insulin resistance and inflammation. These factors are also linked to intestinal dysbiosis. Additionally, the chronic consumption of diets rich in saturated fats results in body weight gain, hormonal resistances and unfavorable changes in the microbiome composition. The intake of Lactobacilli has already been shown to improve dysbiosis along with metabolism and mood. Yet, the beneficial role and the underlying mechanism of Lactobacillus rhamnosus GG (LGG) to improve emotional behavior in established diet-induced obese conditions are, so far, unknown. To characterize the role of LGG in diet-induced obesity, female and male C57BL/6N mice were fed a semi-synthetic low-fat diet (LFD, 10 % kcal from fat) or a conventional high-fat diet (HFD, 45 % kcal from fat) for initial 6 weeks, which was followed by daily oral gavage of vehicle or 1x10^8 CFU of LGG until the end of the experiment. Mice were subjected to basic metabolic and extensive behavioral phenotyping, with a focus on emotional behavior. Moreover, composition of cecal gut microbiome, metabolomic profile in plasma and cerebrospinal fluid was investigated and followed by molecular analyses. Both HFD-feeding and LGG application resulted in sex-specific differences. While LGG prevented the increase of plasma insulin, adrenal gland weight and hyperactivity in diet-induced obese female mice, there was no regulation of anxiodepressive-like behavior. In contrast, metabolism of male mice did not benefit from LGG application, but strikingly, LGG decreased specifically depressive-like behavior in the Mousetail Suspension Test which was confirmed by the Splash Test characterizing motivation for ’self-care’. The microbiome analysis in male mice revealed that HFD-feeding, but not LGG application, altered cecal microbiome composition, indicating a direct effect of LGG on behavioral regulation. However, in female mice, both HFD-feeding and LGG application resulted in changes of microbiome composition, which presumably affected metabolism. Moreover, as diet-induced obese female mice unexpectedly did not exhibit anxiodepressive-like behavior, follow-up analyses were conducted in male mice. Here, HFD-feeding significantly altered abundance of plasma lipids whereas LGG decreased branched chain amino acids which associated with improved emotional behavior. In nucleus accumbens (NAcc) and VTA/SN, which belong to the dopaminergic system, LGG restored HFD-induced decrease of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, on gene expression level. Lastly, transcriptome analysis in the NAcc identified gene expression of cholecystokinin as a potential mediator of the effect of LGG on HFD-induced emotional alterations. In summary, this thesis revealed the beneficial effects of LGG application on emotional alterations in established diet-induced obesity. Furthermore, both HFD-feeding and LGG treatment exhibited sex-specific effects, resulting in metabolic improvements in female mice while LGG application mitigated depressive-like behavior in obese male mice along with a molecular signature of restored dopamine synthesis and neuropeptide signaling. N2 - n adipösen Patienten liegt eine erhöhte Prävalenz von Depressionen und Angsterkrankungen vor. Dies liegt unter anderem an einer gemeinsamen Pathogenese, der eine Insulinresistenz sowie ein chronischer Entzündungszustand zugrunde liegen. Diese Faktoren sind mit einer intestinalen Dysbiose assoziiert, die auch durch eine Fehlernährung, beispielsweise mit einer fettreichen Diät, hervorgerufen werden kann. Es konnte bereits gezeigt werden, dass die Aufnahme von Laktobazillen nicht nur eine Dysbiose und den Stoffwechsel verbessert, sondern sich auch positiv auf das Gemüt auswirken kann. Ob jedoch Lactobacillus rhamnosus GG in der Lage ist, in einem Zustand der etablierten ernährungsbedingten Fettleibigkeit das emotionale Verhalten zu verbessern und welche Mechanismen zugrunde liegen, ist noch ungeklärt. Um die Rolle von LGG bei ernährungsbedingter Fettleibigkeit zu charakterisieren, wurden weibliche und männliche C57BL/6N Mäuse mit einer semi-synthetischen Niedrigfettdiät (LFD, 10 % kcal aus Fett) oder einer konventionellen Hochfettdiät (HFD, 45 % kcal aus Fett) für die ersten 6 Wochen gefüttert, um den Zustand einer Adipositas zu etablieren. Anschließend haben die Mäuse eine tägliche perorale Applikation eines Vehikels oder 1x10^8 KBE LGG bis zum Versuchsende erhalten. Die Mäuse wurden einer allgemeinen metabolischen Charakterisierung und einer umfassenden Verhaltensphänotypisierung unterzogen, die Aufschlüsse über das emotionale Verhalten liefern sollen. Darüber hinaus wurde die Zusammensetzung des Darmmikrobioms bestimmt, im Plasma und in der Zerebrospinalflüssigkeit das Metabolitprofil untersucht und durch molekulare Analysen ergänzt. Sowohl die HFD-Fütterung als auch die LGG-Applikation führten zu geschlechtsspezifischen Unterschieden. Während LGG den diätinduzierten Anstieg von Plasmainsulin, ein erhöhtes Nebennierengewicht und Hyperaktivität in weiblichen Mäusen verhinderte, wurde das emotionale Verhalten nicht reguliert. Im Gegensatz dazu profitierte der Stoffwechsel männlicher Mäuse nicht von der LGG-Anwendung, jedoch war LGG in der Lage, spezifisch das depressiv-ähnliches Verhalten zu verbessern, was durch eine Analyse des zielgerichteten Verhaltens bestätigt wurde. Die Mikrobiomanalyse ergab, dass die Diät, jedoch nicht LGG, die Zusammensetzung des Darmmikrobioms in männlichen Mäusen verändert, was auf eine direkte Rolle von LGG in der Verhaltensregulation hindeutet. Im Vergleich dazu war das Darmmikrobiom in weiblichen Mäusen durch die Diät als auch durch LGG verändert, was zu den positiven Veränderungen der Stoffwechselparameter geführt haben könnte. Da weibliche Mäuse weder durch die HFD-Fütterung noch durch die LGG-Gabe einen Effekt auf emotionales Verhalten aufwiesen, wurden die Folgeanalysen bei männlichen Mäusen durchgeführt. Während die HFD-Fütterung das Vorkommen von Plasmalipiden veränderte, lagen aufgrund der LGG-Gabe verzweigtkettige Aminosäuren verringert vor, was mit einem verbessertem emotionalen Verhalten assoziierte. In den dopaminergen Gehirnregionen Nucleus Accumbens (NAcc) und VTA/SN revertierte LGG die HFD-induzierte Reduktion der Tyrosinhydroxylase Genexpression, des geschwindigkeitsbegrenzenden Enzyms in der Dopaminsynthese. Abschließend wurde eine Transkriptomanalyse mittels RNA Sequencing durchgeführt, welche die Genexpression von Cholezystokinin im NAcc als potenzieller Mediator in der Wirkung von LGG bei HFD-induzierten emotionalen Veränderungen identifizierte. Zusammenfassend konnten in dieser Arbeit die positiven Auswirkungen der LGG-Gabe auf emotionales Verhalten bei etablierter ernährungsbedingter Fettleibigkeit gezeigt werden.. Sowohl die HFD-Fütterung als auch die LGG-Gabe führten zu geschlechtsspezifischen Effekten, was zu Stoffwechselverbesserungen bei weiblichen Mäusen führte, während die LGG-Gabe das depressiv-ähnliche Verhalten bei männlichen Mäusen abschwächte. Zudem wurden auf Genexpressionsebene Tyrosinhydroxylase und Cholezystokinin identifiziert, die potentiell den Effekt von LGG auf das emotionale Verhalten in einem Modell etablierter ernährungsbedingter Fettleibigkeit vermitteln. KW - obesity KW - insulin resistance KW - probiotics KW - lactobacillus KW - depression KW - emotionality Y1 - 2022 ER - TY - JOUR A1 - Mumm, Rebekka A1 - Hermanussen, Michael T1 - A short note on the BMI and on secular changes in BMI JF - Human biology and public health N2 - Human size changes over time with worldwide secular trends in height, weight, and body mass index (BMI). There is general agreement to relate the state of nutrition to height and weight, and to ratios of weight-to-height. The BMI is a ratio. It is commonly used to classify underweight, overweight and obesity in adults. Yet, the BMI is inappropriate to provide any immediate information on body composition. It is accepted that the BMI is “a simple index to classify underweight, overweight and obesity in adults”. It is stated that “policies, programmes and investments need to be “nutrition-sensitive”, which means they must have positive impacts on nutrition”. It is also stated that “a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions“. But these statements are neither warranted by arithmetic considerations, nor by historic evidence. Measuring the BMI is an appropriate screening tool for detecting an unusual weight-to-height ratio, but the BMI is an inappropriate tool for estimating body composition, or suggesting medical and health policy decisions. KW - body mass index KW - secular trend KW - weight-to-height ratio KW - malnutrition KW - obesity Y1 - 2021 U6 - https://doi.org/10.52905/hbph.v2.17 SN - 2748-9957 IS - 2 PB - Universitätsverlag Potsdam CY - Potsdam ER - TY - JOUR A1 - Warschburger, Petra A1 - Gmeiner, Michaela Silvia A1 - Morawietz, Marisa A1 - Rinck, Mike T1 - Evaluation of an approach-avoidance training intervention for children and adolescents with obesity BT - a randomized placebo-controlled prospective trial JF - European eating disorders review : the professional journal of the Eating Disorders Associatio N2 - This study evaluated the efficacy of approach-avoidance training as an additional treatment for children and adolescents with obesity seeking inpatient treatment. Two hundred thirty-two participants (8-16years, 53.9% girls) were randomly assigned either to multisession approach-avoidance (IG) or to placebo training (CG). As outcomes, cognitive biases post intervention, body mass index, eating behaviour, food intake, self-regulation, and weight-related quality of life were assessed, also at 6- and 12-month follow-up. Modification of approach-avoidance bias was observed, but lacked in transfer over sessions and in generalization to attention and association bias. After 6months, the IG reported less problematic food consumption, higher self-regulation, and higher quality of life; effects did not persist until the 12-month follow-up; no significant interaction effects were observed regarding weight course. Despite there was no direct effect on weight course, approach-avoidance training seems to be associated with promising effects on important pillars for weight loss. Further research concerning clinical effectiveness is warranted. KW - approach-avoidance training KW - child KW - cognitive bias modification KW - intervention KW - obesity Y1 - 2018 U6 - https://doi.org/10.1002/erv.2607 SN - 1072-4133 SN - 1099-0968 VL - 26 IS - 5 SP - 472 EP - 482 PB - Wiley CY - Hoboken ER - TY - JOUR A1 - Krstic, Jelena A1 - Reinisch, Isabel A1 - Schupp, Michael A1 - Schulz, Tim Julius A1 - Prokesch, Andreas T1 - p53 functions in adipose tissue metabolism and homeostasis JF - International journal of molecular sciences N2 - As a tumor suppressor and the most frequently mutated gene in cancer, p53 is among the best-described molecules in medical research. As cancer is in most cases an age-related disease, it seems paradoxical that p53 is so strongly conserved from early multicellular organisms to humans. A function not directly related to tumor suppression, such as the regulation of metabolism in nontransformed cells, could explain this selective pressure. While this role of p53 in cellular metabolism is gradually emerging, it is imperative to dissect the tissue-and cell-specific actions of p53 and its downstream signaling pathways. In this review, we focus on studies reporting p53's impact on adipocyte development, function, and maintenance, as well as the causes and consequences of altered p53 levels in white and brown adipose tissue (AT) with respect to systemic energy homeostasis. While whole body p53 knockout mice gain less weight and fat mass under a high-fat diet owing to increased energy expenditure, modifying p53 expression specifically in adipocytes yields more refined insights: (1) p53 is a negative regulator of in vitro adipogenesis; (2) p53 levels in white AT are increased in diet-induced and genetic obesity mouse models and in obese humans; (3) functionally, elevated p53 in white AT increases senescence and chronic inflammation, aggravating systemic insulin resistance; (4) p53 is not required for normal development of brown AT; and (5) when p53 is activated in brown AT in mice fed a high-fat diet, it increases brown AT temperature and brown AT marker gene expression, thereby contributing to reduced fat mass accumulation. In addition, p53 is increasingly being recognized as crucial player in nutrient sensing pathways. Hence, despite existence of contradictory findings and a varying density of evidence, several functions of p53 in adipocytes and ATs have been emerging, positioning p53 as an essential regulatory hub in ATs. Future studies need to make use of more sophisticated in vivo model systems and should identify an AT-specific set of p53 target genes and downstream pathways upon different (nutrient) challenges to identify novel therapeutic targets to curb metabolic diseases KW - p53 KW - adipose tissue KW - metabolic syndrome KW - obesity KW - adipogenesis KW - insulin resistance Y1 - 2018 U6 - https://doi.org/10.3390/ijms19092622 SN - 1422-0067 VL - 19 IS - 9 PB - MDPI CY - Basel ER - TY - JOUR A1 - Castaño Martínez, María Teresa A1 - Schumacher, Fabian A1 - Schumacher, Silke A1 - Kochlik, Bastian Max A1 - Weber, Daniela A1 - Grune, Tilman A1 - Biemann, Ronald A1 - McCann, Adrian A1 - Abraham, Klaus A1 - Weikert, Cornelia A1 - Kleuse, Burkhard A1 - Schürmann, Annette A1 - Laeger, Thomas T1 - Methionine restriction prevents onset of type 2 diabetes in NZO mice JF - The FASEB journal : the official journal of the Federation of American Societies for Experimental Biology N2 - Dietary methionine restriction (MR) is well known to reduce body weight by increasing energy expenditure (EE) and insulin sensitivity. An elevated concentration of circulating fibroblast growth factor 21 (FGF21) has been implicated as a potential underlying mechanism. The aims of our study were to test whether dietary MR in the context of a high-fat regimen protects against type 2 diabetes in mice and to investigate whether vegan and vegetarian diets, which have naturally low methionine levels, modulate circulating FGF21 in humans. New Zealand obese (NZO) mice, a model for polygenic obesity and type 2 diabetes, were placed on isocaloric high-fat diets (protein, 16 kcal%; carbohydrate, 52 kcal%; fat, 32 kcal%) that provided methionine at control (Con; 0.86% methionine) or low levels (0.17%) for 9 wk. Markers of glucose homeostasis and insulin sensitivity were analyzed. Among humans, low methionine intake and circulating FGF21 levels were investigated by comparing a vegan and a vegetarian diet to an omnivore diet and evaluating the effect of a short-term vegetarian diet on FGF21 induction. In comparison with the Con group, MR led to elevated plasma FGF21 levels and prevented the onset of hyperglycemia in NZO mice. MR-fed mice exhibited increased insulin sensitivity, higher plasma adiponectin levels, increased EE, and up-regulated expression of thermogenic genes in subcutaneous white adipose tissue. Food intake and fat mass did not change. Plasma FGF21 levels were markedly higher in vegan humans compared with omnivores, and circulating FGF21 levels increased significantly in omnivores after 4 d on a vegetarian diet. These data suggest that MR induces FGF21 and protects NZO mice from high-fat diet-induced glucose intolerance and type 2 diabetes. The normoglycemic phenotype in vegans and vegetarians may be caused by induced FGF21. MR akin to vegan and vegetarian diets in humans may offer metabolic benefits via increased circulating levels of FGF21 and merits further investigation.-Castano-Martinez, T., Schumacher, F., Schumacher, S., Kochlik, B., Weber, D., Grune, T., Biemann, R., McCann, A., Abraham, K., Weikert, C., Kleuser, B., Schurmann, A., Laeger, T. Methionine restriction prevents onset of type 2 diabetes in NZO mice. KW - energy expenditure KW - hyperglycemia KW - obesity KW - vegan KW - vegetarian Y1 - 2019 U6 - https://doi.org/10.1096/fj.201900150R SN - 0892-6638 SN - 1530-6860 VL - 33 IS - 6 SP - 7092 EP - 7102 PB - Federation of American Societies for Experimental Biology CY - Bethesda ER - TY - JOUR A1 - John, Cathleen A1 - Grune, Jana A1 - Ott, Christiane A1 - Nowotny, Kerstin A1 - Deubel, Stefanie A1 - Kühne, Arne A1 - Schubert, Carola A1 - Kintscher, Ulrich A1 - Regitz-Zagrosek, Vera A1 - Grune, Tilman T1 - Sex Differences in Cardiac Mitochondria in the New Zealand Obese Mouse JF - Frontiers in Endocrinology N2 - Background: Obesity is a risk factor for diseases including type 2 diabetes mellitus (T2DM) and cardiovascular disorders. Diabetes itself contributes to cardiac damage. Thus, studying cardiovascular events and establishing therapeutic intervention in the period of type T2DM onset and manifestation are of highest importance. Mitochondrial dysfunction is one of the pathophysiological mechanisms leading to impaired cardiac function. Methods: An adequate animal model for studying pathophysiology of T2DM is the New Zealand Obese (NZO) mouse. These mice were maintained on a high-fat diet (HFD) without carbohydrates for 13 weeks followed by 4 week HFD with carbohydrates. NZO mice developed severe obesity and only male mice developed manifest T2DM. We determined cardiac phenotypes and mitochondrial function as well as cardiomyocyte signaling in this model. Results: The development of an obese phenotype and T2DM in male mice was accompanied by an impaired systolic function as judged by echocardiography and MyH6/7 expression. Moreover, the mitochondrial function only in male NZO hearts was significantly reduced and ERK1/2 and AMPK protein levels were altered. Conclusions: This is the first report demonstrating that the cardiac phenotype in male diabetic NZO mice is associated with impaired cardiac energy function and signaling events. KW - NZO KW - heart KW - obesity KW - mitochondrial function KW - echocardiography KW - systolic function Y1 - 2018 U6 - https://doi.org/10.3389/fendo.2018.00732 SN - 1664-2392 VL - 9 PB - Frontiers Research Foundation CY - Lausanne ER - TY - JOUR A1 - Warschburger, Petra A1 - Zitzmann, Jana T1 - Does an Age-Specific Treatment Program Augment the Efficacy of a Cognitive-Behavioral Weight Loss Program in Adolescence and Young Adulthood? BT - Results from a Controlled Study JF - Nutrients N2 - Research on weight-loss interventions in emerging adulthood is warranted. Therefore, a cognitive-behavioral group treatment (CBT), including development-specific topics for adolescents and young adults with obesity (YOUTH), was developed. In a controlled study, we compared the efficacy of this age-specific CBT group intervention to an age-unspecific CBT group delivered across ages in an inpatient setting. The primary outcome was body mass index standard deviation score (BMI-SDS) over the course of one year; secondary outcomes were health-related and disease-specific quality of life (QoL). 266 participants aged 16 to 21 years (65% females) were randomized. Intention-to-treat (ITT) and per-protocol analyses (PPA) were performed. For both group interventions, we observed significant and clinically relevant improvements in BMI-SDS and QoL over the course of time with small to large effect sizes. Contrary to our hypothesis, the age-specific intervention was not superior to the age-unspecific CBT-approach. KW - adolescents KW - emerging adults KW - behavioral weight loss KW - obesity KW - controlled trial KW - quality of life Y1 - 2019 U6 - https://doi.org/10.3390/nu11092053 SN - 2072-6643 VL - 2019 IS - 11 PB - MDPI CY - Basel ER - TY - JOUR A1 - Jopp, Eilin A1 - Scheffler, Christiane A1 - Hermanussen, Michael T1 - Prevention and anthropology JF - Journal of biological and clinical anthropology : Anthropologischer Anzeiger ; Mitteilungsorgan der Gesellschaft für Anthropologie N2 - Screening is an important issue in medicine and is used to early identify unrecognised diseases in persons who are apparently in good health. Screening strongly relies on the concept of "normal values". Normal values are defined as values that are frequently observed in a population and usually range within certain statistical limits. Screening for obesity should start early as the prevalence of obesity consolidates already at early school age. Though widely practiced, measuring BMI is not the ultimate solution for detecting obesity. Children with high BMI may be "robust" in skeletal dimensions. Assessing skeletal robustness and in particularly assessing developmental tempo in adolescents are also important issues in health screening. Yet, in spite of the necessity of screening investigations, appropriate reference values are often missing. Meanwhile, new concepts of growth diagrams have been developed. Stage line diagrams are useful for tracking developmental processes over time. Functional data analyses have efficiently been used for analysing longitudinal growth in height and assessing the tempo of maturation. Convenient low-cost statistics have also been developed for generating synthetic national references. KW - screening KW - obesity KW - skeletal robustness KW - developmental tempo Y1 - 2014 U6 - https://doi.org/10.1127/0003-5548/2014/0384 SN - 0003-5548 VL - 71 IS - 1-2 SP - 135 EP - 141 PB - Schweizerbart CY - Stuttgart ER - TY - JOUR A1 - Sun, Sheng-Yun A1 - Huang, Jin A1 - Meng, Min-Jie A1 - Lu, Jia-Hai A1 - Hocher, Berthold A1 - Liu, Kang-Li A1 - Yang, Qin-He A1 - Zhu, Xiao-Feng T1 - Improvement of lipid profile and reduction of body weight by Shan He Jian Fei Granules in high fat diet-induced obese rats JF - Clinical laboratory : the peer reviewed journal for clinical laboratories and laboratories related to blood transfusion N2 - Background: The goal was to study lipid profiles (TG, TC, LDL, HDL), effects on serum leptin, and fat tissue adiponectin, and resistin as well as body weight effects of Shan He Jian Fei Granules (SHJFG) in rats on a high fat diet. Methods: Rats were randomly divided into five groups: normal control group fed with normal fat diet, rats on high fat diet receiving low dosage, middle dosage, high dosage of Shan He Jian Fei Granules (SHJFG) as well as a high fat diet group receiving placebo. Rats were treated for 8 weeks. Body weight and naso-anal length of each rat were recorded and Lee's index was calculated. Serum TG, TC, LDL, HDL and leptin concentrations were analyzed. The gene expressions of adiponectin and resistin in adipose tissues were tested by RT-PCR. Results: Compared to the high-fat diet group, body weights, Lee's indexes, weight of fat tissues and serum TG, TC, LDL and leptin of SHJFG groups significantly decreased (p<0.05), whereas mRNA expressions of adiponectin and resistin of SHJFG groups significantly increased (p<0.05). Conclusions: SHJFG could significantly lower body weight and serum TG, TC, and LDL of obese rats. The effects of SHJFG in lowering leptin synthesis and raising mRNA expression of adiponectin and resistin in fat tissues may act as part of the mechanisms in lowering body weight of obese rats. Further studies are needed to demonstrate whether SHJFG may also reduce overall cardiovascular morbidity and mortality like other lipid lowering drugs. KW - obesity KW - high-fat diet KW - Shan He Jian Fei Granules (SHJFG) KW - lipid KW - adiponectin KW - resistin KW - leptin Y1 - 2012 SN - 1433-6510 VL - 58 IS - 1-2 SP - 81 EP - 87 PB - Clin Lab Publ., Verl. Klinisches Labor CY - Heidelberg ER - TY - JOUR A1 - Vickers, Steven P. A1 - Cheetham, Sharon C. A1 - Birmingham, Gareth D. A1 - Rowley, Helen L. A1 - Headland, Katie R. A1 - Dickinson, Keith A1 - Grempler, Rolf A1 - Hocher, Berthold A1 - Mark, Michael A1 - Klein, Thomas T1 - Effects of the DPP-4 Inhibitor, Linagliptin, in Diet-Induced obese rats a comparison in Naive and Exenatide-Treated Animals JF - Clinical laboratory : the peer reviewed journal for clinical laboratories and laboratories related to blood transfusion N2 - Background: To assess the chronic effect of the DPP-4 inhibitor, linagliptin, alone, in combination with exenatide, and during exenatide withdrawal, in diet-induced obese (DIO) rats. Methods: Female Wistar rats were exposed to a cafeteria diet to induce obesity. Animals were then dosed with vehicle or linagliptin (3 mg/kg PO) orally once-daily for a 28 day period. In a subsequent study, rats received exenatide (either 3 or 30 mu g/kg/day) or vehicle by osmotic mini-pump for 28 days. In addition, groups of animals were dosed orally with linagliptin either alone or in combination with a 3 mu g/kg/day exenatide dose for the study duration. In a final study, rats were administered exenatide (30 mu g/kg/day) or vehicle by osmotic mini-pump for eleven days. Subsequently, exenatide-treated animals were transferred to vehicle or continued exenatide infusion for a further ten days. Animals transferred from exenatide to vehicle were also dosed orally with either vehicle or linagliptin. In all studies, body weight, food and water intake were recorded daily and relevant plasma parameters and carcass composition were determined. Results: In contrast to exenatide, linagliptin did not significantly reduce body weight or carcass fat in DIO rats versus controls. Linagliptin augmented the effect of exenatide to reduce body fat when given in combination but did not affect the body weight response. In rats withdrawn from exenatide, weight regain was observed such that body weight was not significantly different to controls. Linagliptin reduced weight regain after withdrawal of exenatide such that a significant difference from controls was evident. Conclusions: These data demonstrate that linagliptin does not significantly alter body weight in either untreated or exenatide-treated DIO rats, although it delays weight gain after exenatide withdrawal. This finding may suggest the utility of DPP-4 inhibitors in reducing body weight during periods of weight gain. KW - Dipeptidyl peptidase 4 inhibitor KW - Linagliptin KW - obesity KW - weight loss Y1 - 2012 U6 - https://doi.org/10.7754/Clin.Lab.2011.110919 SN - 1433-6510 VL - 58 IS - 7-8 SP - 787 EP - 799 PB - Clin Lab Publ., Verl. Klinisches Labor CY - Heidelberg ER -